Correction: Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies (Proceedings of the National Academy of Sciences of the United States of America (2015) 112, (2000-2005) DOI: 10.1073/pnas.1416694112);Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 7, 2015, Pages 2000-2005

  Venetz, Dario ^a   Hess, Christian ^a   Lin, Chia Wei ^a   Aebi, Markus ^a   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

Author keywords

Armed antibody; Glycosylation; Interleukin 9; Site specific glycan analysis; Tumor targeting

Indexed keywords

GLYCAN DERIVATIVE; HUMAN MONOCLONAL ANTIBODY; HYBRID PROTEIN; INTERLEUKIN 9; MONOCLONAL ANTIBODY F8; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; ANTIBODY; PRIMER DNA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOAVAILABILITY; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CHO CELL LINE; DEGLYCOSYLATION; DRUG TARGETING; EX VIVO STUDY; EXTRAVASATION; FEMALE; GEL FILTRATION; GLYCOSYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYDROPHILIC INTERACTION CHROMATOGRAPHY; IMMUNOFLUORESCENCE MICROSCOPY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; STABLE EXPRESSION; SURFACE PLASMON RESONANCE; TANDEM MASS SPECTROMETRY; TERATOCARCINOMA CELL LINE; TISSUE DISTRIBUTION; TRANSIENT EXPRESSION; TURNOVER TIME; ANIMAL; CONTRAST MEDIUM EXTRAVASATION; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; MOUSE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION;

ANIMALS; ANTIBODIES; BASE SEQUENCE; DNA PRIMERS; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FEMALE; GLYCOSYLATION; MICE; POLYMERASE CHAIN REACTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84923197393     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1503039112     Document Type: Erratum

References (33)

1. Walsh G (2014) Biopharmaceutical benchmarks 2014. Nat Biotechnol 32(10):992-1000.
2. Walsh G, Jefferis R (2006) Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 24(10):1241-1252.
3. Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313(5787):670-673.
4. Ferrara C, et al. (2011) Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci USA 108(31):12669-12674.
5. Sinclair AM, Elliott S (2005) Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. J Pharm Sci 94(8):1626-1635.
6. Elliott S, et al. (2003) Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21(4):414-421.
7. Jones AJ, et al. (2007) Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology 17(5):529-540.
8. Wu AM, Senter PD (2005) Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 23(9):1137-1146.
9. Hess C, Venetz D, Neri D (2014) Emerging classes of armed antibody therapeutics against cancer. Medchemcomm 5(4):408-431.
10. Morell AG, Gregoriadis G, Scheinberg IH, Hickman J, Ashwell G (1971) The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem 246(5):1461-1467.
11. Lee SJ, et al. (2002) Mannose receptor-mediated regulation of serum glycoprotein homeostasis. Science 295(5561):1898-1901.
12. Ghaderi D, Taylor RE, Padler-Karavani V, Diaz S, Varki A (2010) Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat Biotechnol 28(8):863-867.
13. Villa A, et al. (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122(11):2405-2413.
14. Rybak JN, Roesli C, Kaspar M, Villa A, Neri D (2007) The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res 67(22):10948-10957.
15. Perrino E, et al. (2014) Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Cancer Res 74(9):2569-2578.
16. Purwar R, et al. (2012) Robust tumor immunity to melanoma mediated by interleukin- 9-producing T cells. Nat Med 18(8):1248-1253.
17. Lu Y, et al. (2014) Tumor-specific IL-9-producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers. Proc Natl Acad Sci USA 111(6):2265-2270.
18. Rajendra Y, Kiseljak D, Baldi L, Hacker DL, Wurm FM (2011) A simple high-yielding process for transient gene expression in CHO cells. J Biotechnol 153(1-2):22-26.
19. Gutbrodt KL, Casi G, Neri D (2014) Antibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice. Mol Cancer Ther 13(7):1772-1776.
20. Graff CP, Wittrup KD (2003) Theoretical analysis of antibody targeting of tumor spheroids: Importance of dosage for penetration, and affinity for retention. Cancer Res 63(6):1288-1296.
21. Hughes RC (2001) Galectins as modulators of cell adhesion. Biochimie 83(7):667-676.
22. Liu FT, Rabinovich GA (2005) Galectins as modulators of tumour progression. Nat Rev Cancer 5(1):29-41.
23. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6(5): 343-357.
24. Schiestl M, et al. (2011) Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 29(4):310-312.
25. Brik A, Ficht S, Wong CH (2006) Strategies for the preparation of homogenous glycoproteins. Curr Opin Chem Biol 10(6):638-644.
26. Schwarz F, et al. (2010) A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation. Nat Chem Biol 6(4):264-266.
27. Meuris L, et al. (2014) GlycoDelete engineering of mammalian cells simplifies N-glycosylation of recombinant proteins. Nat Biotechnol 32(5):485-489.
28. Anumula KR (1995) Rapid quantitative determination of sialic acids in glycoproteins by high-performance liquid chromatography with a sensitive fluorescence detection. Anal Biochem 230(1):24-30.
29. Bigge JC, et al. (1995) Nonselective and efficient fluorescent labeling of glycans using 2-amino benzamide and anthranilic acid. Anal Biochem 230(2):229-238.
30. Dell A, et al. (1994) Mass spectrometry of carbohydrate-containing biopolymers. Methods Enzymol 230:108-132.
31. Ceroni A, et al. (2008) GlycoWorkbench: A tool for the computer-assisted annotation of mass spectra of glycans. J Proteome Res 7(4):1650-1659.
32. Wis̈niewski JR, Zougman A, Nagaraj N, Mann M (2009) Universal sample preparation method for proteome analysis. Nat Methods 6(5):359-362.
33. Varki A, et al. (2009) Symbol nomenclature for glycan representation. Proteomics 9(24):5398-5399.